Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2025-03-31 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE INTERIM RESULTS FROM ITS U.S. PHASE IB TRIAL WITH ASC30, A POTENTIALLY FIRST-IN-CLASS SUBCUTANEOUS INJECTION SMALL MOLECULE GLP-1R AGONIST
Regulatory Filings Classification · 75% confidence The document is a corporate announcement filed under Hong Kong Listing Rules disclosing positive interim clinical trial results for a Phase Ib study. It is not an Annual or Interim financial report, not an earnings release, not a management change, nor proxy or voting materials. It is a general regulatory announcement of inside information under the Listing Rules. Therefore it falls into the fallback category “Regulatory Filings” (RNS).
2025-03-31 English
RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
Annual Report Classification · 95% confidence The document is a 'Results Announcement' for World Houseware (Holdings) Limited for the year ended 31 December 2024. It contains detailed audited consolidated financial statements, including the Statement of Profit or Loss, Statement of Financial Position, and extensive notes to the financial statements. While it is titled an 'announcement', it provides the full substantive financial data and analysis for the fiscal year, which qualifies it as an Annual Report (10-K) equivalent under the provided definitions for a company listed on the Hong Kong Stock Exchange. FY 2024
2025-03-27 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 AND CHANGE IN THE USE OF PROCEEDS
Earnings Release Classification · 93% confidence The document is an audited annual results announcement for the year ended December 31, 2024, containing key financial highlights, corporate profile, MD&A and pipeline updates. It is a regulatory announcement of full-year financial results (initial summary release), not a full statutory annual report or 10-K. Therefore, it matches the definition of an Earnings Release (ER). FY 2024
2025-03-26 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 89% confidence The document is a board meeting date announcement to approve and release the final results for the year ended 31 December 2024 and consider a final dividend. It does not contain the actual results or dividend details, but merely notifies shareholders of the timing of report approval and release. This matches the definition of a Report Publication Announcement (RPA).
2025-03-17 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 80% confidence The document is a notice of a Board meeting to approve annual results and consider dividends. It does not present actual financial results or any changes in board composition, nor is it a proxy statement or dividend notice. It is a generic regulatory announcement on the company’s website and stock exchange. There is no dedicated category for meeting notices, so it defaults to the general Regulatory Filings category (RNS).
2025-03-13 English
INSIDE INFORMATION - ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE IB STUDIES OF ASC47 MONOTHERAPY IN AUSTRALIA AND U.S. FDA CLEARANCE OF IND APPLICATION FOR ASC47 IN COMBINATION WITH SEMAGLUTI
Regulatory Filings Classification · 90% confidence The document is an HKEx announcement filed under the Listing Rules, disclosing clinical Phase Ib topline data and FDA IND clearance. It is not a financial/earnings release, board change, dividend notice, or proxy statement—rather it is a generic regulatory announcement (inside information). It does not constitute a full annual or interim report, nor a specific category like M&A or capital change. This falls into the generic Regulatory Filings (RNS) fallback category.
2025-03-12 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.